




CHIMERIC THERAPEUTICS

20
25

CHIMERIC

PIONEERS IN CELL THERAPY

EGM July 23, 2025





DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims

any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.


This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



FY25 IN SUMMARY

Corporate


\$16.6m raised including \$5.6m from US Family Office
Lind facility paid out in full by end of July 2025.
Significant headcount and cost reductions



CHM CDH17

CAR-T

Trial commenced: 5 patients treated
Dose level 1 completed: Stable disease 6mths
Dose level 2 commenced
8/8 successful GMP manufacturing runs



CHM CORE-NK

'OFF THE SHELF' NK


Dose finding completed
Frontline ADVENT AML commenced
2 CRi (Complete response with incomplete blood count recovery)



CHM CDH17

Clinical Trial Update

JULY 2025





CLINICAL PRELIMINARY RESULTS

CHM CDH17 DOSE LEVEL 1

50m Cells	Tumour Type	Status
Patient 1	CRC	No follow up
Patient 2	NET	Stable Disease until day 150 progression
Patient 3	CRC	Stable Disease at day 150
Patient 4	CRC	Progressive Disease at day 28

CRC= Colorectal Cancer (Bowel Cancer)

NET= NeuroEndocrine Tumor (Intestinal NET)



CLINICAL PRELIMINARY RESULTS

CHM CDH17 DOSE LEVEL 2

150m Cells	Tumour Type	Status
Patient 5	CRC	DLT Passed. Pending DAY 28 SCAN
Patient 6	NET	Manufactured to be treated
Patient 7	NET	Manufactured to be treated

CRC= Colorectal Cancer (Bowel Cancer)


NET= NeuroEndocrine Tumor (Intestinal NET)



CHM CORE-NK

Clinical Trial Update

JULY 2025





CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Complete response in AML in two patient of first three dosed

2 / 3 patients

DIAGNOSIS: AML

Not eligible for Chemo or Stem Cell Transplant

SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD

CORE-NK
INFUSION

Patient Doses + SOC

COMPLETE
RESPONSE i

DAY 28

CRi = no signs of cancer in response to treatment
Blood count yet to recover (standard for AML patients)



CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17 CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN

4 sites active

CHM CORE-NK 'OFF THE SHELF' NK

Technology from:



PHASE 1B
TRIAL OPEN

MD Anderson

PHASE 1B
TRIAL OPEN

Case Western

CHM CLTX

Technology from:



Phase 1A completed: COH

PHASE 1B TRIAL

1 site active



INVESTMENT HIGHLIGHTS

4

4 Phase 1 clinical trials
under 3 FDA INDs at 4 leading US centres



Multiple clinical updates
in the next 12mths



Experienced leadership team
in cell therapy clinical development



CHM-CDH17
the ONLY CDH17 CAR-T in clinical trials



First in class
CLTX-CAR for brain cancer



Robust and long life
patent portfolio

CORPORATE PROFILE

Exchange

ASX: CHM

Share Price

\$0.005

52 Week Range

\$0.004 - 0.047

Market Cap

Approx \$10m

Shares on issue

~1.6B


IPO 2021



CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.com



ASX:
CHM